Pulmonem Inc.

Pulmonem Inc. was founded to demonstrate the effectiveness and safety of a reformulated and patented version of Dapsone, a generic drug, to arrest the development of inflammation caused by COVID-19 and help prevent hospitalization of those who become infected. Pulmonem has established manufacturing partnerships that will allow the Company to quickly bring this treatment to market soon after successful completion of clinical trials. Pulmonem is also pursuing solutions for the pediatric market, as well as alternative delivery systems, such as nasal sprays and liquids.